Week in Review: VistaGen Out-Licenses China/Asia Rights for Novel Anxiety Drug to EverInsight in $177 Million Deal

Deals and Financings • VistaGen out-licensed China/Southeast Asia rights for a novel on-demand anxiety treatment to China's EverInsight in a $177 million deal; ChinaBio® advised VistaGen on the transaction; • Beijing's SinocellTech completed a $181 million IPO on Shanghai's STAR Board and nearly tripled in price during its initial trading session; • Hangzhou Betta Pharma signed a $135 million agreement to in-license China rights for two immunotherapies from Agenus of Massachusetts; • Hutchison China MediTech (Chi-Med) announced a $100 million private placement with General Atlantic to support development of its seven-candidate portfolio; • Shanghai's Genor Biopharma signed a $46 million deal with G1 Therapeutics for Asia rights to a CDK4/6 inhibitor designed to work with other IO therapies; • Simcha, a novel biotech developing immunotherapies based on improved cytokines, raised $25 million in a Series A financing from two China investors; • Sophonix of Boston closed a $14 million Series B financing led by Zero2IPO to develop point-of-care-tests for pathological and immuno-diagnostic tests;   COVID-19 Pandemic • Beijing's Institute of Medical Biology started a China Phase II trial of its inactivated COVID-19 vaccine that will enroll 942 healthy volunteers; • The Taiwan Food and Drug Administration granted conditional approval for the use of remdesivir in patients with severe COVID-19 disease; Trials and Approvals • Shanghai Henlius was approved to launch its denosumab biosimilar (HLX14) in China as a treatment for postmenopausal osteoporosis; • Merck/MSD said China approved the fifth indication for Keytruda, its anti-PD-1 drug, as a second-line treatment for esophageal cancer; • InxMed (Shanghai), a clinical stage biotech, announced early data showed its focal adhesion kinase (FAK) inhibitor was effective in overcoming drug resistance; Company News • WuXi NextCODE, a genomics services company, will jettison its China operations and adopt a new name, Genuity Science; • AnchorDx, a Guangzhou diagnostics company, said its next-gen blood-based DNA cancer test will screen for six types of cancer at a $100 price point. Stock Symbols: (SHA: 688520) (NSDQ: VTGN) (SHZ: 300558) (NSDQ: AGEN) (NSDQ/AIM: HCM) (NSDQ: GTHX) (HK: 2696) (NYSE: MRK) Share this with colleagues: // //